RAD-140 (Testolone) — Dosing, Cycles, Half-Life & Side Effects

RAD-140 (Testolone) is a selective androgen receptor modulator (SARM) with a half-life of 45 hours. WARNING: FDA has issued safety warnings about SARM-associated liver injury. RAD-140 has been specifically linked to drug-induced liver injury cases. Highly selective SARM with strong anabolic effects. Not approved for human use - research chemical only. NO human cycling/performance trials exist (LoRusso 2022 Phase 1 in postmenopausal mBC patients). Primary risks include strong HPTA suppression. This page is educational harm-reduction reference compiled from peer-reviewed literature — not medical advice, not an endorsement, not a recommendation to use. Consult a licensed clinician before any decision.

Quick Facts

ClassSelective Androgen Receptor Modulators
Half-life45 hours
Detection window60 days
AromatizationNo
HepatotoxicityMedium-High
Suppression8/10
17α-alkylatedNo
Administrationoral

Typical Dosing Ranges

Common dose range: 10-30mg/day (NOTE: No human dosing studies exist)

Cycle length: 8 weeks maximum (due to liver concerns)

Time to steady state: ~9 days

Dose ranges are compiled from published pharmacokinetic studies and community-reported usage. Where a value is community-reported rather than clinically studied, this page and its structured data flag it. Lower end of any range is always the safer starting point.

Stacking Considerations

  • No structural stacking blockers. Standard harm-reduction rules apply: minimize total androgen load, minimize oral exposure, and monitor bloodwork.

PCT Requirements

  • This compound causes clinically meaningful HPTA suppression. Post-cycle therapy is recommended.
  • Depot clearance estimate: ~9 days post-last-dose before SERM start (5 × apparent depot half-life of 45h).
  • Never stack two SERMs. Extend a single SERM (tamoxifen OR enclomiphene/clomiphene) rather than combining.
  • Use the cycle planner to generate a full protocol based on your complete stack, not this compound alone.

Side Effect Profile

  • FDA WARNING: SARM-associated liver injury - RAD-140 specifically implicated
  • High suppression
  • Hepatotoxicity risk - multiple case reports of liver injury
  • NO human clinical trials - all data from preclinical studies
  • Not approved for human use
  • WADA prohibited
  • Expensive
  • Long detection time due to 45-hour half-life

Known Interactions

  • RAD-140 (Testolone) + Ligandrol (LGD-4033)

    moderate — suppressive

    Stacking two suppressive SARMs increases HPTA suppression significantly.

    Recommendation: May require PCT. Consider lower doses or test base.

    Monitor: LH, FSH, Total testosterone

  • RAD-140 (Testolone) + s23

    moderate — suppressive

    S23 is highly suppressive. Combination may cause significant hormonal disruption.

    Recommendation: Test base strongly recommended. PCT required.

    Monitor: Full hormone panel

Related compounds

Monitoring (Bloodwork & Vitals)

  • Comprehensive metabolic panel (baseline, mid-cycle, post-cycle)
  • Lipid panel (total cholesterol, HDL, LDL, triglycerides)
  • CBC (hemoglobin, hematocrit — watch for erythrocytosis)
  • Sex-hormone panel (Total T, Free T, Estradiol sensitive, SHBG, LH, FSH)
  • Blood pressure (weekly self-check; flag systolic >140 or diastolic >90)

Baseline bloodwork is recommended before any cycle. Discontinue if liver enzymes exceed 3× upper limit of normal or if hematocrit exceeds 54%.

Frequently Asked Questions

What is the half-life of RAD-140 (Testolone)?

RAD-140 (Testolone) has a half-life of approximately 45 hours. Clearance estimate: 45h × 5 = 225h = 9.4 days. This figure is used to determine injection frequency (for esters) and post-cycle clearance timing.

What is the typical dose range for RAD-140 (Testolone)?

Commonly reported ranges for RAD-140 (Testolone): 10-30mg/day (NOTE: No human dosing studies exist). Cycle length: 8 weeks maximum (due to liver concerns). These are compiled from published studies and community-reported usage — individual response varies and lower end is always preferred.

Does RAD-140 (Testolone) suppress natural testosterone?

RAD-140 (Testolone) causes strong suppression of the HPTA axis (score 8/10). Post-cycle therapy (PCT) is recommended after use.

Is RAD-140 (Testolone) liver toxic?

Hepatotoxicity rating: Medium-High. Non-17αα compound — liver stress is lower but still warrants periodic monitoring during a cycle.

Does RAD-140 (Testolone) aromatize to estrogen?

Aromatization profile: No. Minimal to no aromatization expected, so aromatase inhibitors are not typically indicated for this compound alone.

What is RAD-140 (Testolone) typically used for?

RAD-140 (Testolone) is commonly used for: EXPERIMENTAL - Not approved for human use, Research purposes only. Intended-use context does not imply safety — every use case carries the same underlying pharmacological risks.

Citations

  1. LoRusso P et al.. 2022. Clin Breast Cancer — Half-life 44.7 hours from Phase I breast cancer study
  2. Miller CP et al.. 2011. ACS Med Chem Lett — Preclinical data: T suppressed approximately 50% across all dose levels in primates
  3. Barbara M et al.. 2020. Clinical case report — RAD-140/LGD-4033 combination DILI case report
  4. Basaria S et al.. 2013. J Gerontol A Biol Sci Med Sci — RAD-140 SARM class analog (LGD-4033 phase 1 data) — suppression of LH/FSH/total testosterone at supraphysiologic doses; supports suppressionScore 8/10
  5. Leung K et al.. 2022. Ochsner J — RAD-140 Drug-Induced Liver Injury case report — cholestatic DILI at recreational dose; consistent with the LoRusso 2022 Phase 1 trial AST 59.1% / ALT 45.5% / bilirubin 27.3% TEAE signal. hepatotoxicity 7/10 (highest-hepatotoxic SARM)
  6. Liu E et al. (SARM class extrapolation). 2025. Subst Use Misuse — SARMs generally lower CV impact than AAS but RAD-140 elevates LDL, suppresses HDL; supports cardioStrain 5/10
  7. Miller CP, et al. Design, synthesis, and preclinical characterization of the selective androgen receptor modulator (SARM) RAD140. ACS Med Chem Lett 2011 (PRECLINICAL ONLY)
  8. FDA Safety Statement: 'SARMs have been linked to serious safety concerns including increased risk of heart attack, stroke, and liver damage'
  9. Barbara M, et al. RAD140: An investigational selective androgen receptor modulator for muscle wasting. Drugs Today. 2021;57(7):447-462

Disclaimer

StackItSmart is an independent harm-reduction reference. The content above is compiled from peer-reviewed literature and is not medical advice, not an endorsement, and not a recommendation to use RAD-140 (Testolone). Performance-enhancing compounds carry legal, endocrine, cardiovascular, and hepatic risks. Consult a licensed clinician before any decision. StackItSmart does not provide sourcing, procurement, or dosing prescriptions.

Skip to main content